| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Centre d’Immunologie de Marseille-Luminy, Marseille, France
To study the relation between the form of an Ag and the response to it, we compared presentation in vitro with hen egg lysozyme (HEL)-specific T cells from TCR transgenic mice of free HEL and liposome-encapsulated HEL by different APC. HEL-specific splenic B cells or bone marrow-derived dendritic cells were incubated with free HEL or HEL-containing liposomes targeted by Ab to either surface Ig, the Fc receptor, or MHC class I and II molecules. Ag presentation by HEL-specific B cells was at least 100-fold more efficient for HEL in surface Ig-targeted liposomes than free HEL taken up by the same receptor or HEL in liposomes targeted to class I or II molecules. Ag presentation by dendritic cells from Fc receptor-targeted vesicles was augmented 1,000–10,000-fold compared with free Ag or nontargeted liposomes, but presentation was also efficient when Ag was targeted to class I or II molecules. These results indicate that Ag-specific B cells and dendritic cells can be equally efficient in stimulating IL-2 production by Ag-specific T cells from unimmunized TCR transgenic mice when the Ag is multivalent and taken up by appropriate receptors. In contrast to B cells, which require engagement of surface Ig for optimal presentation, dendritic cells may present Ag by means of several different cell surface molecules.
This article has been cited by other articles:
|
|
 |
|
  D. H. Schuurhuis, N. van Montfoort, A. Ioan-Facsinay, R. Jiawan, M. Camps, J. Nouta, C. J. M. Melief, J. S. Verbeek, and F. Ossendorp Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol., April 15, 2006; 176(8): 4573 - 4580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mahnke, Y. Qian, S. Fondel, J. Brueck, C. Becker, and A. H. Enk Targeting of Antigens to Activated Dendritic Cells In vivo Cures Metastatic Melanoma in Mice Cancer Res., August 1, 2005; 65(15): 7007 - 7012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. He, T. T. Moore, F. O. Eko, D. Lyn, G. A. Ananaba, A. Martin, S. Singh, L. James, J. Stiles, C. M. Black, et al. Molecular Basis for the Potency of IL-10-Deficient Dendritic Cells as a Highly Efficient APC System for Activating Th1 Response J. Immunol., April 15, 2005; 174(8): 4860 - 4869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. van Broekhoven, C. R. Parish, C. Demangel, W. J. Britton, and J. G. Altin Targeting Dendritic Cells with Antigen-Containing Liposomes: A Highly Effective Procedure for Induction of Antitumor Immunity and for Tumor Immunotherapy Cancer Res., June 15, 2004; 64(12): 4357 - 4365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Getahun, J. Dahlstrom, S. Wernersson, and B. Heyman IgG2a-Mediated Enhancement of Antibody and T Cell Responses and Its Relation to Inhibitory and Activating Fc{gamma} Receptors J. Immunol., May 1, 2004; 172(9): 5269 - 5276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Buatois, M. Baillet, S. Becart, N. Mooney, L. Leserman, and P. Machy MHC Class II-Peptide Complexes in Dendritic Cell Lipid Microdomains Initiate the CD4 Th1 Phenotype J. Immunol., December 1, 2003; 171(11): 5812 - 5819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Wahl, E. Nossner, K. Kronenberger, R. Gangnus, H. Pohla, M. S. Staege, H.-J. Kolb, M. Hallek, and R. Mocikat Vaccination against B-cell Chronic Lymphocytic Leukemia with Trioma Cells: Preclinical Evaluation Clin. Cancer Res., September 15, 2003; 9(11): 4240 - 4246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Arigita, L. Bevaart, L. A. Everse, G. A. Koning, W. E. Hennink, D. J. A. Crommelin, J. G. J. van de Winkel, M. J. van Vugt, G. F. A. Kersten, and W. Jiskoot Liposomal Meningococcal B Vaccination: Role of Dendritic Cell Targeting in the Development of a Protective Immune Response Infect. Immun., September 1, 2003; 71(9): 5210 - 5218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kronenberger, A. Dieckmann, M. Selmayr, J. Strehl, U. Wahl, H. Lindhofer, G. Kraal, and R. Mocikat Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells Blood, February 15, 2002; 99(4): 1327 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Machy, K. Serre, M. Baillet, and L. Leserman Induction of MHC Class I Presentation of Exogenous Antigen by Dendritic Cells Is Controlled by CD4+ T Cells Engaging Class II Molecules in Cholesterol-Rich Domains J. Immunol., February 1, 2002; 168(3): 1172 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rivera, C.-C. Chen, N. Ron, J. P. Dougherty, and Y. Ron Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations Int. Immunol., December 1, 2001; 13(12): 1583 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Chikh, S. Kong, M. B. Bally, J.-C. Meunier, and M.-P. M. Schutze-Redelmeier Efficient Delivery of Antennapedia Homeodomain Fused to CTL Epitope with Liposomes into Dendritic Cells Results in the Activation of CD8+ T Cells J. Immunol., December 1, 2001; 167(11): 6462 - 6470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. You, J. Hester, L. Rollins, G. C. Spagnoli, P. van der Bruggen, and S.-Y. Chen A Retrogen Strategy for Presentation of an Intracellular Tumor Antigen as an Exogenous Antigen by Dendritic Cells Induces Potent Antitumor T Helper and CTL Responses Cancer Res., January 1, 2001; 61(1): 197 - 205. [Abstract] [Full Text]
|
|
|
|
|
|
T. Keler, P. M. Guyre, L. A. Vitale, K. Sundarapandiyan, J. G. J. van de Winkel, Y. M. Deo, and R. F. Graziano Targeting Weak Antigens to CD64 Elicits Potent Humoral Responses in Human CD64 Transgenic Mice J. Immunol., December 15, 2000; 165(12): 6738 - 6742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ignatius, K. Mahnke, M. Rivera, K. Hong, F. Isdell, R. M. Steinman, M. Pope, and L. Stamatatos Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8+ T-cell responses in vivo Blood, November 15, 2000; 96(10): 3505 - 3513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. You, X. F. Huang, J. Hester, L. Rollins, C. Rooney, and S.-Y. Chen Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization Pathway J. Immunol., October 15, 2000; 165(8): 4581 - 4591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Corinti, D. Medaglini, C. Prezzi, A. Cavani, G. Pozzi, and G. Girolomoni Human Dendritic Cells Are Superior to B Cells at Presenting a Major Histocompatibility Complex Class II-Restricted Heterologous Antigen Expressed on Recombinant Streptococcus gordonii Infect. Immun., April 1, 2000; 68(4): 1879 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Zimmermann, P. Rovere, J. Trucy, K. Serre, P. Machy, F. Forquet, L. Leserman, and J. Davoust Engagement of B Cell Receptor Regulates the Invariant Chain-Dependent MHC Class II Presentation Pathway J. Immunol., March 1, 1999; 162(5): 2495 - 2502. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
